Democrats Press White House on Retatrutide Patient
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Democratic lawmakers are pressing the Trump administration over the identity of a 79-year-old who received special access in April to Eli Lilly's experimental obesity drug retatrutide
- Eli Lilly and the FDA offered the drug via the FDA's "compassionate use" program, a pathway reserved for patients with serious and immediately life-threatening medical issues
- The patient has refractory obesity, obstructive sleep apnea, and pulmonary hypertension
- Lawmakers are specifically asking whether the recipient is the president or another prominent figure
- STAT first reported the compassionate-use arrangement on Tuesday
Why it matters: The compassionate-use pathway is meant for patients with serious and immediately life-threatening conditions, so the political fight turns on whether a sitting president's access to an experimental drug receives the same public disclosure as any other patient — and whether the FDA's special-access program was used appropriately for a 79-year-old with multiple comorbidities.
Ask SkimNews
